US8586712B2 - Humanized antibodies - Google Patents

Humanized antibodies Download PDF

Info

Publication number
US8586712B2
US8586712B2 US12/748,304 US74830410A US8586712B2 US 8586712 B2 US8586712 B2 US 8586712B2 US 74830410 A US74830410 A US 74830410A US 8586712 B2 US8586712 B2 US 8586712B2
Authority
US
United States
Prior art keywords
position
antibody
seq id
variant
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US12/748,304
Other versions
US20110044976A1 (en
Inventor
Fang Fang
Lori Kohlstaedt
John Reno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perlan Therapeutics Inc
Original Assignee
Perlan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/US1998/025422 priority Critical patent/WO1999027964A1/en
Priority to US55544600A priority
Priority to US09/910,483 priority patent/US20030035798A1/en
Priority to US11/519,322 priority patent/US7696324B2/en
Application filed by Perlan Therapeutics Inc filed Critical Perlan Therapeutics Inc
Priority to US12/748,304 priority patent/US8586712B2/en
Publication of US20110044976A1 publication Critical patent/US20110044976A1/en
Application granted granted Critical
Publication of US8586712B2 publication Critical patent/US8586712B2/en
Assigned to PERLAN THERAPEUTICS, INC. reassignment PERLAN THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FANG, FANG, KOHLSTAEDT, LORI, RENO, JOHN
Anticipated expiration legal-status Critical
Application status is Expired - Fee Related legal-status Critical

Links